Screening Glucose Challenge Test in Pregnancy Can Identify Women With an Adverse Postpartum Cardiovascular Risk Factor Profile: Implications for Cardiovascular Risk Reduction.

Background The 1-hour glucose challenge test (GCT) is routinely performed in pregnancy to screen for gestational diabetes mellitus. Remarkably, it has recently emerged that the GCT can also predict a woman's future risk of cardiovascular disease, although the mechanistic basis of this relationship is unclear. In this context we hypothesized that a higher GCT may identify women with an otherwise unrecognized adverse cardiovascular phenotype. Thus, we sought to evaluate the relationship between the antepartum GCT and subsequent postpartum cardiovascular risk factor profile. Methods and Results In this study 503 women completed a screening GCT in late second trimester and then underwent cardiometabolic characterization at 3 months postpartum, whereupon traditional (blood pressure, glucose, lipids) and nontraditional (apolipoprotein B, C-reactive protein, adiponectin) cardiovascular risk factors were compared across GCT tertiles. At 3 months postpartum, each of the following risk factors progressively worsened from the lowest to middle to highest GCT tertile: fasting glucose (P=0.0002), 2-hour glucose (P<0.0001), total cholesterol:high-density lipoprotein cholesterol (P=0.0004), high-density lipoprotein cholesterol (P=0.004), triglycerides (P=0.001), apolipoprotein B (P=0.001), and adiponectin (P=0.02). On multiple linear regression analyses, the GCT emerged as a significant independent predictor of higher fasting glucose (P=0.0006), 2-hour glucose (P<0.0001), total cholesterol: high-density lipoprotein cholesterol (P=0.0004), triglycerides (P=0.001), low-density lipoprotein cholesterol (P=0.01), and apolipoprotein B (P=0.004) and of lower high-density lipoprotein cholesterol (P=0.02) and adiponectin (P=0.0099). Moreover, these independent associations persisted after excluding women who had gestational diabetes mellitus. Conclusions The antepartum GCT can identify women with an adverse underlying cardiovascular risk factor phenotype.